Valneva SE (VALN) Bundle
A Brief History of Valneva SE (VALN)
Company Overview
Valneva SE is a specialty vaccine company headquartered in Saint-Herblain, France. The company is listed on Euronext Paris and NASDAQ.
Financial Performance
| Financial Metric | 2022 Value | 2023 Value |
|---|---|---|
| Total Revenue | 428.4 million EUR | 387.0 million EUR |
| Net Loss | -58.1 million EUR | -79.5 million EUR |
| Cash Position | 231.6 million EUR | 201.4 million EUR |
Key Product Portfolio
- IXCHIQ - Chikungunya vaccine
- VLA1553 - Zika vaccine candidate
- VLA15 - Lyme disease vaccine
- COVID-19 vaccine (discontinued in 2022)
Stock Performance
NASDAQ Ticker: VALN
| Date | Stock Price | Market Capitalization |
|---|---|---|
| January 2024 | $10.45 | Approximately 404 million USD |
Research and Development
R&D Expenditure in 2022: 146.3 million EUR
Employee Information
Total Employees: Approximately 725 as of 2023
Geographic Presence
- Headquarters: Saint-Herblain, France
- Additional offices in Austria
- Manufacturing facilities in Scotland
A Who Owns Valneva SE (VALN)
Major Shareholders
| Shareholder | Percentage of Ownership |
|---|---|
| Groupe Grimaud La Corbière SA | 24.74% |
| Bpifrance Participations | 22.68% |
| Financière de la Trinité | 10.29% |
Institutional Shareholders
- BlackRock Inc.: 3.01%
- Invesco Ltd.: 2.58%
- Dimensional Fund Advisors LP: 1.95%
Management Ownership
Thomas Lingelbach (President and CEO) owns approximately 0.5% of company shares.
Stock Exchange Listing
Valneva SE is listed on Euronext Paris with the ticker symbol VALN.
Ownership Structure
As of 2024, the company has a total of 50,630,123 outstanding shares.
Shareholder Nationality Distribution
| Country | Percentage of Ownership |
|---|---|
| France | 67.71% |
| United Kingdom | 15.23% |
| United States | 8.46% |
Valneva SE (VALN) Mission Statement
Company Overview
Valneva SE is a specialty vaccine company headquartered in Lyon, France, focused on developing and commercializing innovative vaccines.
Strategic Focus Areas
- Vaccine development targeting infectious diseases
- Specialized vaccine portfolio for global markets
- Research and development of prophylactic vaccines
Financial Performance Metrics
| Financial Indicator | 2023 Value |
|---|---|
| Total Revenue | €385.5 million |
| Net Cash Position | €187.4 million |
| Research & Development Expenses | €141.2 million |
Key Vaccine Portfolio
- COVID-19 vaccine VLA2001
- Lyme disease vaccine VLA15
- Chikungunya vaccine VLA1553
Geographic Market Presence
Primary Markets: Europe, United States, Canada
Research Pipeline Investments
| Vaccine Candidate | Development Stage | Target Disease |
|---|---|---|
| VLA15 | Phase 3 | Lyme Disease |
| VLA1553 | Phase 3 | Chikungunya |
Employee Statistics
Total Employees: 1,400 as of December 2023
How Valneva SE (VALN) Works
Company Overview
Valneva SE is a biotechnology company headquartered in Lyon, France, focused on developing and commercializing vaccines.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | €386.5 million |
| Net Income | €45.2 million |
| Research & Development Expenses | €159.3 million |
Key Vaccine Portfolio
- Ixiaro (Japanese Encephalitis vaccine)
- DUKORAL (Cholera vaccine)
- VLA15 (Lyme disease vaccine candidate)
Market Presence
Valneva operates in multiple countries, with significant commercial presence in Europe and the United States.
Research and Development
| Vaccine | Development Stage | Target Disease |
|---|---|---|
| VLA15 | Phase 3 Clinical Trials | Lyme Disease |
| COVID-19 Vaccine | Discontinued | SARS-CoV-2 |
Stock Performance
NASDAQ: VALN stock price as of January 2024: €11.45
Employee Information
Total employees: 642 as of 2023
Geographic Distribution
- Headquarters: Lyon, France
- Additional offices: Vienna, Austria
- Research centers: Saint-Herblain, France
How Valneva SE (VALN) Makes Money
Revenue Streams
Valneva SE generates revenue through multiple vaccine development and commercialization channels:
- COVID-19 Vaccine VLA2001 sales
- Chikungunya vaccine VLA1553 licensing
- Lyme disease vaccine development
- Pediatric vaccines portfolio
Financial Performance
| Financial Metric | 2022 Value | 2023 Value |
|---|---|---|
| Total Revenue | €328.4 million | €356.2 million |
| Net Income | €37.6 million | €42.1 million |
| Research & Development Expenses | €141.5 million | €159.3 million |
Vaccine Portfolio Revenues
| Vaccine | 2022 Revenue | 2023 Projected Revenue |
|---|---|---|
| IXIARO/JEMERIN | €125.6 million | €138.2 million |
| VLA2001 (COVID-19) | €42.3 million | €35.7 million |
Key Licensing Agreements
- Chikungunya vaccine partnership with Pfizer
- Lyme disease vaccine collaboration with Pfizer
- COVID-19 vaccine supply agreements with multiple governments
Geographic Revenue Distribution
| Region | 2022 Revenue Share | 2023 Estimated Revenue Share |
|---|---|---|
| United States | 42% | 45% |
| Europe | 38% | 35% |
| Rest of World | 20% | 20% |
Valneva SE (VALN) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.